同行评审盲检测试验 (P-BAT):为国家监管的大麻市场提供无信实验室质量保证的框架
Stuart Procter1, Grayson L Baird1, Jason Iannuccilli2
1PureVita Labs LLC, 153 James P Murphy Ind Hwy , West Warwick, 02893-2382, United States.
Journal of cannabis research
|January 20, 2025
概括
一个新的同行评审盲测试 (P-BAT) 框架通过让实验室盲目测试竞争对手产品来确保大麻实验室的准确性. 这种缺乏信任的系统优先考虑消费者安全和准确的产品标签,而不是行业的激励措施.
科学领域:
- 大麻科学 大麻科学
- 实验室的质量保证工作.
- 消费者安全 消费者安全
背景情况:
- 大麻测试旨在通过限制有害污染物和提供准确的标签来保护消费者.
- 现有的行业激励措施造成利益冲突,可能会损害实验室准确性,有利于种植者和经销商.
研究的目的:
- 提出一个质量保证框架,以解决大麻实验室测试中不正当的激励措施.
- 引入同行评审盲测试 (P-BAT) 作为提高测试准确性和透明度的解决方案.
- 通过可靠的产品数据,加强消费者决策.
主要方法:
- 拟议的同行评审盲测试 (P-BAT) 涉及实验室以盲目的方式测试竞争对手和自己的产品.
- 这种验证过程确保在测试期间,实验室和产品的身份是未知的.
- 该框架的设计是具有成本效益,透明和缺乏信任的.
主要成果:
- P-BAT旨在提高实验室的性能和问责制.
- 该系统还可以识别诸如产品改和不良储存实践等问题.
- 来自P-BAT的公开可用的数据将赋予消费者权力.
结论:
- P-BAT提供了一种无信任,成本高效和透明的解决方案,以提高大麻测试的完整性.
- 这一框架鼓励实验室对消费者负责,而不仅仅是行业利益相关者.
- 实施P-BAT将提高大麻市场的消费者安全和知情购买决策.
相关概念视频
Clinically Relevant Drug Product Specifications: Methods of Establishment
300
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
300
Therapeutic Drug Monitoring: Drug Analysis Methods
342
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
342


